Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 4 | 2023 | 366 | 1.390 |
Why?
|
| Lung Transplantation | 10 | 2024 | 313 | 1.150 |
Why?
|
| Chromoblastomycosis | 1 | 2024 | 3 | 0.950 |
Why?
|
| Hemangioma, Capillary | 1 | 2022 | 7 | 0.800 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2022 | 8 | 0.790 |
Why?
|
| Thromboembolism | 1 | 2022 | 122 | 0.750 |
Why?
|
| Lung Diseases | 3 | 2022 | 275 | 0.740 |
Why?
|
| Epoprostenol | 1 | 2020 | 46 | 0.680 |
Why?
|
| Drug Substitution | 1 | 2020 | 27 | 0.680 |
Why?
|
| Respiratory Insufficiency | 2 | 2016 | 162 | 0.680 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 232 | 0.650 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 598 | 0.640 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 257 | 0.580 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 1098 | 0.570 |
Why?
|
| Multiple Chronic Conditions | 1 | 2016 | 5 | 0.550 |
Why?
|
| Mycobacterium avium Complex | 1 | 2015 | 6 | 0.490 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2015 | 5 | 0.490 |
Why?
|
| Macrolides | 1 | 2015 | 30 | 0.490 |
Why?
|
| Postoperative Complications | 4 | 2016 | 2314 | 0.440 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 142 | 0.420 |
Why?
|
| Heart-Lung Transplantation | 2 | 2017 | 19 | 0.400 |
Why?
|
| Immunosuppressive Agents | 4 | 2024 | 979 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 798 | 0.320 |
Why?
|
| Quality of Life | 1 | 2016 | 1682 | 0.300 |
Why?
|
| Lung | 3 | 2022 | 1292 | 0.280 |
Why?
|
| Antifungal Agents | 2 | 2024 | 123 | 0.270 |
Why?
|
| Bronchodilator Agents | 2 | 2006 | 66 | 0.270 |
Why?
|
| Sirolimus | 3 | 2013 | 162 | 0.260 |
Why?
|
| Splenic Rupture | 1 | 2006 | 7 | 0.260 |
Why?
|
| Gastroparesis | 1 | 2006 | 14 | 0.260 |
Why?
|
| Graft Rejection | 5 | 2017 | 1076 | 0.250 |
Why?
|
| Asthma | 3 | 2019 | 984 | 0.250 |
Why?
|
| Humans | 28 | 2024 | 89985 | 0.240 |
Why?
|
| Lung Diseases, Fungal | 1 | 2003 | 18 | 0.220 |
Why?
|
| Fungemia | 1 | 2003 | 15 | 0.220 |
Why?
|
| Reproductive Health Services | 1 | 2023 | 20 | 0.210 |
Why?
|
| Diagnosis, Differential | 3 | 2024 | 1606 | 0.210 |
Why?
|
| Transplant Recipients | 1 | 2024 | 142 | 0.210 |
Why?
|
| Opportunistic Infections | 1 | 2003 | 60 | 0.210 |
Why?
|
| Ipratropium | 1 | 2002 | 18 | 0.210 |
Why?
|
| Helium | 1 | 2002 | 10 | 0.210 |
Why?
|
| Endarterectomy | 1 | 2022 | 23 | 0.200 |
Why?
|
| Respiratory Function Tests | 1 | 2002 | 140 | 0.200 |
Why?
|
| Tissue and Organ Procurement | 2 | 2020 | 360 | 0.190 |
Why?
|
| Pulmonary Fibrosis | 1 | 2023 | 138 | 0.190 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2004 | 262 | 0.180 |
Why?
|
| Male | 14 | 2024 | 42690 | 0.180 |
Why?
|
| Infusions, Subcutaneous | 1 | 2020 | 3 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2022 | 323 | 0.170 |
Why?
|
| Hepatitis B | 1 | 2020 | 76 | 0.170 |
Why?
|
| Walk Test | 1 | 2020 | 24 | 0.170 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 53 | 0.170 |
Why?
|
| Administration, Inhalation | 1 | 2020 | 192 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 437 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 416 | 0.160 |
Why?
|
| Exercise Test | 1 | 2020 | 166 | 0.160 |
Why?
|
| Thymoma | 1 | 2019 | 30 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2022 | 432 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2019 | 30 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2022 | 958 | 0.160 |
Why?
|
| Thymus Neoplasms | 1 | 2019 | 43 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 2 | 2013 | 150 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2020 | 186 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2019 | 84 | 0.150 |
Why?
|
| Cardiac Catheterization | 1 | 2020 | 307 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2020 | 463 | 0.150 |
Why?
|
| Oxygen | 1 | 2002 | 746 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 241 | 0.140 |
Why?
|
| Primary Graft Dysfunction | 1 | 2017 | 41 | 0.140 |
Why?
|
| Stem Cells | 1 | 2019 | 376 | 0.140 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 199 | 0.140 |
Why?
|
| Female | 15 | 2020 | 46602 | 0.120 |
Why?
|
| Consensus | 1 | 2017 | 366 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2019 | 689 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 944 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 327 | 0.110 |
Why?
|
| Middle Aged | 11 | 2020 | 26159 | 0.110 |
Why?
|
| Transcriptome | 1 | 2019 | 661 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1862 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2887 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2017 | 584 | 0.110 |
Why?
|
| Azathioprine | 2 | 2010 | 124 | 0.110 |
Why?
|
| Tacrolimus | 2 | 2010 | 369 | 0.100 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2010 | 33 | 0.090 |
Why?
|
| Hospitals, Religious | 1 | 2010 | 29 | 0.090 |
Why?
|
| Aged | 4 | 2024 | 19262 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2010 | 785 | 0.080 |
Why?
|
| Biopsy | 1 | 2013 | 1184 | 0.080 |
Why?
|
| Adult | 6 | 2020 | 26827 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 161 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2013 | 4329 | 0.070 |
Why?
|
| Isoproterenol | 1 | 2006 | 62 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2010 | 283 | 0.070 |
Why?
|
| Albuterol | 1 | 2006 | 35 | 0.070 |
Why?
|
| Mucins | 1 | 2006 | 39 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2006 | 74 | 0.070 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2006 | 17 | 0.070 |
Why?
|
| Gastric Emptying | 1 | 2006 | 25 | 0.060 |
Why?
|
| Prognosis | 2 | 2004 | 3800 | 0.060 |
Why?
|
| Primary Myelofibrosis | 1 | 2005 | 67 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 79 | 0.060 |
Why?
|
| Decision Trees | 1 | 2004 | 61 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 334 | 0.060 |
Why?
|
| Pulmonary Emphysema | 1 | 2004 | 37 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2004 | 58 | 0.060 |
Why?
|
| Subclavian Artery | 1 | 2004 | 43 | 0.060 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 90 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2005 | 144 | 0.060 |
Why?
|
| Radiography | 1 | 2006 | 808 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2004 | 166 | 0.060 |
Why?
|
| Cryptococcosis | 1 | 2003 | 11 | 0.050 |
Why?
|
| Candidiasis | 1 | 2003 | 37 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2006 | 267 | 0.050 |
Why?
|
| Aspergillosis | 1 | 2003 | 41 | 0.050 |
Why?
|
| Aerosols | 1 | 2002 | 47 | 0.050 |
Why?
|
| Telomere | 1 | 2023 | 119 | 0.050 |
Why?
|
| Leukocytes | 1 | 2023 | 209 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 387 | 0.050 |
Why?
|
| Carcinoma | 1 | 2005 | 438 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 264 | 0.050 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2020 | 10 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 23 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2020 | 16 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 848 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 45 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 91 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 841 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2019 | 296 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 1604 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 505 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 149 | 0.030 |
Why?
|
| Forced Expiratory Volume | 2 | 2006 | 126 | 0.030 |
Why?
|
| Global Health | 1 | 2017 | 193 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 2327 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 2370 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2395 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2013 | 162 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 614 | 0.020 |
Why?
|
| Oklahoma | 1 | 2010 | 2 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2010 | 33 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2010 | 48 | 0.020 |
Why?
|
| Prednisone | 1 | 2010 | 255 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 312 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2010 | 172 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 855 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2010 | 284 | 0.020 |
Why?
|
| Reoperation | 1 | 2010 | 604 | 0.020 |
Why?
|
| Adolescent | 2 | 2013 | 9345 | 0.020 |
Why?
|
| Length of Stay | 1 | 2010 | 749 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2006 | 44 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 908 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 1899 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2006 | 278 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2005 | 50 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 12 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 30 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 22 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 2004 | 22 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 66 | 0.010 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2004 | 4 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 846 | 0.010 |
Why?
|
| Heart Rate | 1 | 2006 | 498 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 222 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 198 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2006 | 1714 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 906 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 6785 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 5358 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 811 | 0.010 |
Why?
|
| Smoking | 1 | 2004 | 625 | 0.010 |
Why?
|
| United States | 1 | 2013 | 7114 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 1469 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 5562 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 1778 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 27536 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 9216 | 0.010 |
Why?
|
| Child | 1 | 2006 | 7242 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 2677 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 8277 | 0.010 |
Why?
|